Allergy Therapeutics delivered substantial update on pollen and peanut allergy remedies at a US industry gathering.
Allergy Therapeutics is a completely integrated commercial biotechnology company focused on allergy vaccines. The Group is focused on allergens that can be treated with subcutaneous and sublingual immunotherapy like, pollens, house dust mites, pets and moulds.
At the 2022 American Academy of Allergy, Asthma, and Immunology Annual Meeting in Phoenix, Arizona, the group delivered promising new results from its two lead immunotherapy programmes.
Allergy Therapeutics Update
Allergy Therapeutics reported extensive results from the G309 exploratory field study, indicating safety and effectiveness of Grass MATA MPL, the Group’s short-course injectable allergen-specific immunotherapy (SCIT) candidate for allergic rhinoconjunctivitis caused by grass pollen. This was a multi-centre, double-blind, placebo-controlled, randomised and parallel-group clinical experiment with participants from 13 different locations in Germany and the United States.
In comparison to the historically used placebo group’s effective dose on the clinical outcome, the presentations disclosed a more prominent, clinically significant, and statically relevant progress in the primary combined symptom and medication score for the conventional and extended posology groups, respectively.
This increase of 39.5% is higher than the estimated number of 36.8% announced by the Group in October2021, when the two placebo groups were pooled. These findings indicate the superior treatment effect sizes reached after six Grass MATA MPL injections.
The Group also provided post-hoc analyses of a previous Phase II grass trial, showcasing the robust prognosis of the baseline CPT (conjunctival provocation test) score for IgG4 increase after SCIT treatment, laying the groundwork for the impending vital G306 Phase III trial, which will begin in the autumn of 2022.
The company also released information of a pollen monitoring network set up by Allergy Therapeutics in the U. S., complete with central reading procedures for correctly estimating daily pollen counts and determining the peak grass pollen season, which is crucial for determining the G306 Phase III trial’s primary study results.
Dr. Mohamed Shamji, an Imperial College London Reader in Immunology and Allergy, delivered findings from the VLP001 ex-vivo biomarker study.
The study looked at the group’s peanut allergy vaccine candidate, VLP Peanut. When compared to the predominant allergen, Ara h2, the data indicated that VLP Peanut is a hypoallergenic, and leads in a considerable reduction in basophil activation and histamine release in peanut allergic people. These biomarker results show significant help for VLP Peanut’s possible immunologic mode of action in encouraging transferring from the allergic Th2 pathway to the more immunological tolerant Th1 pathway, highlighting VLP Peanut’s potential as a peanut allergy treatment.
Company Vaccine Portfolio
The Group has a vast variety of vaccines at different stages of the pipeline.
The vaccines cater to two forms of therapy which are Modified Allergen Tyrosine Adsorbed (MATA) and Subcutaneous Immunotherapy (SCIT).
Allergy Therapeutics have a handful of drugs which are already on the market or registered which include, hay fever meds, bee and wasp remedies. Peanut allergy remedies are still under Phase 1.
“Demonstrating a nearly 40% reduction in combined symptom and medication score compared to placebo in a grass pollen allergy trial is a significant event in our history. We are very much looking forward to the pivotal G306 clinical trial of our Grass MATA MPL immunotherapy that is due to commence later this year and, if successful, would enable registration in Europe and the US. Such a product would permit patients suffering from grass pollen allergy the opportunity to address the cause of their disease, not just mask their symptoms. I am also very proud to see the data from our VLP001 study being presented internationally – data that provides us with confidence in the product profile of our novel short course peanut allergy vaccine candidate as we head into the clinic later this year,” said Manuel Llobet, Chief Executive Officer, Allergy Therapeutics.